NOK/STYK1 has a strong tendency towards forming aggregates and colocalises with epidermal growth factor receptor in endosomes

Biochemical and Biophysical Research Communications

Volumn 421, Issue 3, 2012, Pages 468-473

  Ding, Xue ^a   Jiang, Qing Bo ^a   Li, Rui ^a   Chen, Shaoyong ^b   Zhang, Shuping ^a  

^a TSINGHUA UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

EGFR; Endosome; NOK STYK1; Subcellular localisation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE; PUTATIVE SERINE THREONINE AND TYROSINE RECEPTOR PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOSOME; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IN VIVO STUDY; LYSOSOME; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION;

CELL MEMBRANE; ENDOSOMES; EPIDERMAL GROWTH FACTOR; HELA CELLS; HUMANS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84860692756     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.016     Document Type: Article

References (26)

1. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
2. Heldin C.H. Dimerization of cell surface receptors in signal transduction. Cell 1995, 80:213-223.
3. Murphy J.E., Padilla B.E., Hasdemir B., Cottrell G.S., Bunnett N.W. Endosomes: a legitimate platform for the signaling train. Proc. Natl. Acad. Sci. USA 2009, 106:17615-17622.
4. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7:169-181.
5. Johnson B.E., Janne P.A. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 2005, 65:7525-7529.
6. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
7. Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., Zha X.M., Polakiewicz R.D., Comb M.J. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 2005, 23:94-101.
8. Shepard H.M., Brdlik C.M., Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J. Clin. Invest. 2008, 118:3574-3581.
9. Fishman M.C., Porter J.A. Pharmaceuticals: a new grammar for drug discovery. Nature 2005, 437:491-493.
10. Liu L., Yu X.Z., Li T.S., Song L.X., Chen P.L., Suo T.L., Li Y.H., Wang S.D., Chen Y., Ren Y.M., Zhang S.P., Chang Z.J., Fu X.Y. A novel protein tyrosine kinase NOK that shares homology with platelet-derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res. 2004, 64:3491-3499.
11. Jackson K.A., Oprea G., Handy J., Kimbro K.S. Aberrant STYK1 expression in ovarian cancer tissues and cell lines. J. Ovarian Res. 2009, 2:15.
12. Amachika T., Kobayashi D., Moriai R., Tsuji N., Watanabe N. Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer 2007, 56:337-340.
13. Kimbro K.S., Duschene K., Willard M., Moore J.A., Freeman S. A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Mol. Biol. Rep. 2008, 35:23-27.
14. Chen Y., Li Y.H., Chen X.P., Gong L.M., Zhang S.P., Chang Z.J., Zhang X.F., Fu X.Y., Liu L. Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice. Cancer Res. 2005, 65:10838-10846.
15. Chung S., Tamura K., Furihata M., Uemura M., Daigo Y., Nasu Y., Miki T., Shuin T., Fujioka T., Nakamura Y., Nakagawa H. Overexpression of the potential kinase serine/threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. Cancer Sci. 2009, 100:2109-2114.
16. Goh L.K., Huang F., Kim W., Gygi S., Sorkin A. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J. Cell Biol. 2010, 189:871-883.
17. Pennock S., Wang Z. Stimulation of cell proliferation by endosomal epidermal growth factor receptor as revealed through two distinct phases of signaling. Mol. Cell Biol. 2003, 23:5803-5815.
18. Li Y.H., Wang Y.Y., Zhong S., Rong Z.L., Ren Y.M., Li Z.Y., Zhang S.P., Chang Z.J., Liu L. Transmembrane helix of novel oncogene with kinase-domain (NOK) influences its oligomerization and limits the activation of RAS/MAPK signaling. Mol. Cells 2009, 27:39-45.
19. Zhang C., Li A., Zhang X., Xiao H. A novel TIP30 protein complex regulates EGF receptor signaling and endocytic degradation. J. Biol. Chem. 2011, 286:9373-9381.
20. Maxfield F.R., McGraw T.E. Endocytic recycling. Nat. Rev. Mol. Cell Biol. 2004, 5:121-132.
21. Avraham R., Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 2011, 12:104-117.
22. Jopling H.M., Howell G.J., Gamper N., Ponnambalam S. The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling. Biochem. Biophys. Res. Commun. 2011, 410:170-176.
23. Mohammadi M., Honegger A., Sorokin A., Ullrich A., Schlessinger J., Hurwitz D.R. Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase. Biochemistry 1993, 32:8742-8748.
24. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 1987, 56:881-914.
25. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
26. Sorkin A., Carpenter G. Interaction of activated EGF receptors with coated pit adaptins. Science 1993, 261:612-615.